Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review

Chan, 2002, The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators, Arch Dermatol, 138, 370, 10.1001/archderm.138.3.370 Fleming, 2000, Cicatricial pemphigoid, J Am Acad Dermatol, 43, 571, 10.1067/mjd.2000.107248 Ojha, 2007, Cicatricial pemphigoid with severe gingival and laryngeal involvement in an 18-year-old female, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 104, 363, 10.1016/j.tripleo.2006.11.030 Lambiel, 2017, Paraneoplastic mucous membrane pemphigoid with ocular and laryngeal involvement, BMJ Case Rep, 2017 Rice, 1990, Immunopathology of cicatricial pemphigoid affecting the conjunctiva, Ophthalmology, 97, 1476, 10.1016/S0161-6420(90)32402-8 Leverkus, 2001, Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230, Br J Dermatol, 145, 998, 10.1046/j.1365-2133.2001.04543.x Bernard, 1990, Studies of cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis, J Invest Dermatol, 94, 630, 10.1111/1523-1747.ep12876206 Kirtschig, 2002, Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review, Arch Dermatol, 138, 380, 10.1001/archderm.138.3.380 Truhan, 1989, Corticosteroids: a review with emphasis on complications of prolonged systemic therapy, Ann Allergy, 62, 375 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, e1000097, 10.1371/journal.pmed.1000097 The Centre for Evidence-Based Medicine Nagelkerke, 2014, Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?, Front Immunol, 5, 674 Okitsu-Negishi, 1994, Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1, Immunol Res, 13, 49, 10.1007/BF02918224 Menezes, 1997, In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations, Int Arch Allergy Immunol, 114, 323, 10.1159/000237689 Ruiz de Souza, 1995, Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin), Eur J Immunol, 25, 1267, 10.1002/eji.1830250521 Ling, 1993, Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo, J Clin Immunol, 13, 302, 10.1007/BF00920238 Dart, 2017, The 2016 Bowman lecture. Conjunctival curses: scarring conjunctivitis 30 years on, Eye (Lond), 31, 301, 10.1038/eye.2016.284 Foster, 1999, Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study, Ophthalmology, 106, 2136, 10.1016/S0161-6420(99)90496-7 Ahmed, 2001, Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy, Arch Dermatol, 137, 1181, 10.1001/archderm.137.9.1181 Ahmed, 2001, Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment, J Am Acad Dermatol, 45, 679, 10.1067/mjd.2001.116339 Ahmed, 2001, Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment, J Am Acad Dermatol, 45, 825, 10.1067/mjd.2001.116337 Mobini, 1995, Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders, Ann Allergy Asthma Immunol, 74, 119 Rutter, 2001, High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin, J Am Acad Dermatol, 44, 1010, 10.1067/mjd.2001.112325 Lamberts, 2018, Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases, Front Immunol, 9, 248, 10.3389/fimmu.2018.00248 Maley, 2016, Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP), J Am Acad Dermatol, 74, 835, 10.1016/j.jaad.2016.01.020 Shetty, 2013, Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature, J Am Acad Dermatol, 68, 499, 10.1016/j.jaad.2012.10.018 He, 2015, Persistence of autoreactive IgA-secreting B cells despite multiple immunosuppressive medications including rituximab, JAMA Dermatol, 151, 646, 10.1001/jamadermatol.2015.59 Kroll, 2013, Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes, J Clin Virol, 57, 115, 10.1016/j.jcv.2013.01.016 Aksoy, 2007, Rituximab-related viral infections in lymphoma patients, Leuk Lymphoma, 48, 1307, 10.1080/10428190701411441 Schuler, 2016, Rituximab and acute retinal necrosis in a patient with scleromalacia and rheumatoid arthritis, Ocul Immunol Inflamm, 24, 96, 10.3109/09273948.2014.999377 Le Roux-Villet, 2011, Rituximab for patients with refractory mucous membrane pemphigoid, Arch Dermatol, 147, 843, 10.1001/archdermatol.2011.54 Ahmed, 2004, Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment, Prog Retin Eye Res, 23, 579, 10.1016/j.preteyeres.2004.05.005 Vilcek, 1991, Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions, J Biol Chem, 266, 7313, 10.1016/S0021-9258(20)89445-9 Lee, 1993, Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid, Invest Ophthalmol Vis Sci, 34, 3522 Razzaque, 2004, Role of macrophage migration inhibitory factor in conjunctival pathology in ocular cicatricial pemphigoid, Invest Ophthalmol Vis Sci, 45, 1174, 10.1167/iovs.03-1138 Razzaque, 2002, Role of enhanced expression of m-CSF in conjunctiva affected by cicatricial pemphigoid, Invest Ophthalmol Vis Sci, 43, 2977